Skip to content

Main Navigation

  • About us
    • Our team
    • Employee stories
    • Working with us
    • Our principles
    • Mission, vision & values
    • History
    • Corporate Social Responsibility
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
    • Academic collaborations
  • Careers
  • Events
  • News
  • Contact us
  • LinkedIn

A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug Interactions

PAGE 32 (2024) Abstr 10834
Kovar C, Kanacher T, Huang F, Wu J, Sailer R, Busse D, Gómez-Mantilla JD, Ince I.
ConferenceDDIPBPK/PBBMSpecial considerations

Pharmetheus Affiliates

Portrait-of-Christina-Kovar_Pharmetheus
Consultant

Christina Kovar

See bio
Portrait-of-Tobias-Kanacher-Pharmetheus
Senior Consultant

Tobias Kanacher

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

info@pharmetheus.com

+46(0)18-51 33 28

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.